Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.65 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | GMNN | O75496 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5227169 | 0.99 | ADORA1 (0.65) | ADORA1ADORA2BADORA2AMEN1GMNN | |
| SCHEMBL6093414 | 0.96 | ADORA1 (0.61) | ADORA1ADORA2BADORA2AMEN1GMNN | |
| SCHEMBL6093056 | 0.90 | ADORA1 (0.57) | ADORA1ADORA2BADORA2AMEN1GMNN | |
| SCHEMBL5229000 | 0.89 | ADORA1 (0.62) | ADORA1ADORA2BADORA2AMEN1GMNN | |
| SCHEMBL6095139 | 0.86 | ADORA1 (0.51) | ADORA1ADORA2BADORA2AMEN1GMNN | |
| SCHEMBL6093921 | 0.85 | ADORA2A (0.50) | ADORA1ADORA2BADORA2AMEN1GMNN | |
| SCHEMBL5229239 | 0.80 | ADORA3 (0.61) | ADORA1ADORA2BADORA2AMEN1GMNN | |
| SCHEMBL4623484 | 0.79 | ADORA1 (1.00) | ADORA1ADORA2BADORA2AMEN1GMNN | |
| SCHEMBL6094137 | 0.78 | ADORA1 (0.41) | ADORA1ADORA2BADORA2AMEN1GMNN | |
| SCHEMBL5229734 | 0.78 | ADORA2B (1.00) | ADORA1ADORA2BADORA2AMEN1GMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7005430-B2 | Fused purine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-02-28 | — | — | US | disclosed |
| EP-1251130-B1 | FUSED PURINE DERIVATIVES | KYOWA HAKKO KOGYO KK (JP) | 2005-02-16 | — | — | EP | disclosed |
| US-20030176698-A1 | Fused purine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| EP-1251130-A1 | FUSED PURINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176698-A1 | Fused purine derivatives | PNP, NSUN2, CYP2W1 | ADORA1 64/4885ADORA2B 206/4885ADORA2A 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.